AlphAIAlphAI — Financial news for AI agents
investing.comOCT 282 min read$GMAB

Genmab stock surges 16% on positive cancer trial results

Genmab (GMAB) shares rose 16% after announcing positive Phase 3 trial results for petosemtamab, showing a 50% reduction in death risk in head and neck cancer patients. The trial met primary endpoints, with a hazard ratio of 0.50. The company plans regulatory submissions and further trials.

Original reporting
investing.com
Published Oct 28, 2026, 1:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The 50% hazard reduction is a strong efficacy signal that could accelerate regulatory submissions and partnership interest.

02

Market read

First‑report of pivotal trial data moves Genmab shares sharply higher, with potential spill‑over to the oncology biotech space.

03

What to watch

Future trial results in colorectal cancer and competitive landscape could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Genmab is a Danish biotech focused on antibody therapeutics; the LiGeR-HN1 trial combines its bispecific antibody with pembrolizumab.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab announced Phase 3 trial results showing a 50% reduction in death risk, driving a 16% share surge.

Expected impact

upward pressure as the market incorporates the survival benefit

Evidence & confidence

First disclosure of pivotal Phase 3 data; shares already jumped 16% on the news.

Market effects

Sector

Biotech sector may see broader rally on positive oncology data.

Regional

European biotech markets could benefit from a Danish company's breakthrough.

Global

Potential impact on global oncology drug pipelines and investor sentiment.

Counterpoint

What could challenge this read

Skeptics may question long‑term efficacy and regulatory hurdles, suggesting caution.

Key entities

  • company
    Genmab A/S

    Danish biotech developing bispecific antibodies.

  • drug
    Pembrolizumab

    PD‑1 inhibitor used as the trial backbone.

Read at source← All news

Related articles

OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min
OCT 28
$GMABHigh

Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab (GMAB) reported positive Phase 3 trial results for petosemtamab in combination with pembrolizumab, showing a 50% reduction in death risk for PD-L1+ head and neck cancer patients. The trial met both primary endpoints, and the company plans to engage regulators and present full results. Petosemtamab is also being evaluated in other Phase 3 trials for different cancers.

finanznachrichten.de2 min
OCT 28
$GMABHighAI 9/10

Why is Genmab stock surging today?

Genmab's stock rose 16.8% after its Phase 3 LiGeR-HN1 trial showed a 50% reduction in death risk for a combination treatment. Analysts upgraded the stock, with JPMorgan raising its price target to DKK 3,500 and TD Cowen to $52.00. The trial results were well-received, with no new safety concerns.

investing.com2 min
OCT 28
$GMABHigh

Genmab’s petosemtamab trial cuts death risk by 50% in cancer

Genmab A/S (GMAB) reported that its Phase 3 trial for petosemtamab met primary endpoints, reducing death risk by 50% in head and neck cancer patients. The combination therapy showed significant improvements in overall survival and response rates, with a hazard ratio of 0.50 and an objective response rate odds ratio of 3.17. The company plans regulatory submissions and further trial evaluations. Head and neck squamous cell carcinoma is the seventh most common cancer globally.

investing.com2 min
OCT 27
$GMABHighAI 8/10

J.P. Morgan upgrades Genmab on cancer drug growth potential

J.P. Morgan upgraded Genmab to 'overweight' and raised its price target to DKr3,500, citing expected positive results from a late-stage trial of its cancer drug petosemtamab. The brokerage anticipates a response rate of at least 40% in head and neck cancer patients, raising its peak sales forecast to $5 billion. It also increased sales forecasts for other drugs, Rina-S and Epkinly, and adjusted its revenue and earnings per share estimates.

finance.yahoo.com2 min